| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 3767 | 2018 |
| An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis MPR Berry, CM Graham, FW McNab, Z Xu, SAA Bloch, T Oni, ... Nature 466 (7309), 973-977, 2010 | 2000 | 2010 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1360 | 2018 |
| Personalized immunomonitoring uncovers molecular networks that stratify lupus patients R Banchereau, S Hong, B Cantarel, N Baldwin, J Baisch, M Edens, ... Cell 165 (3), 551-565, 2016 | 710 | 2016 |
| Peripheral T cell expansion predicts tumour infiltration and clinical response TD Wu, S Madireddi, PE de Almeida, R Banchereau, YJJ Chen, AS Chitre, ... Nature 579 (7798), 274-278, 2020 | 510 | 2020 |
| Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ... Nature medicine 25 (11), 1706-1714, 2019 | 478 | 2019 |
| Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus S Caielli, S Athale, B Domic, E Murat, M Chandra, R Banchereau, ... Journal of Experimental Medicine 213 (5), 697-713, 2016 | 431 | 2016 |
| ctDNA guiding adjuvant immunotherapy in urothelial carcinoma T Powles, ZJ Assaf, N Davarpanah, R Banchereau, BE Szabados, ... Nature 595 (7867), 432-437, 2021 | 355 | 2021 |
| Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade RJ Motzer, R Banchereau, H Hamidi, T Powles, D McDermott, MB Atkins, ... Cancer cell 38 (6), 803-817. e4, 2020 | 320 | 2020 |
| High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade KC Yuen, LF Liu, V Gupta, S Madireddi, S Keerthivasan, C Li, ... Nature medicine 26 (5), 693-698, 2020 | 285 | 2020 |
| A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate S Caielli, DT Veiga, P Balasubramanian, S Athale, B Domic, E Murat, ... Nature medicine 25 (1), 75-81, 2019 | 213 | 2019 |
| Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer NS Patil, BY Nabet, S Müller, H Koeppen, W Zou, J Giltnane, A Au-Yeung, ... Cancer cell 40 (3), 289-300. e4, 2022 | 174 | 2022 |
| IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer TC Wu, K Xu, J Martinek, RR Young, R Banchereau, J George, J Turner, ... Cancer research 78 (18), 5243-5258, 2018 | 161 | 2018 |
| Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus Y Kotliarov, R Sparks, AJ Martins, MP Mulè, Y Lu, M Goswami, L Kardava, ... Nature medicine 26 (4), 618-629, 2020 | 154 | 2020 |
| LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity AT Krishnamurty, JA Shyer, M Thai, V Gandham, MB Buechler, YA Yang, ... Nature 611 (7934), 148-154, 2022 | 125 | 2022 |
| Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections R Banchereau, A Jordan-Villegas, M Ardura, A Mejias, N Baldwin, H Xu, ... PloS one 7 (4), e34390, 2012 | 110 | 2012 |
| Activation of RegIIIβ/γ and interferon γ expression in the intestinal tract of SCID mice: an innate response to bacterial colonisation of the gut SA Keilbaugh, ME Shin, RF Banchereau, LD McVay, N Boyko, D Artis, ... Gut 54 (5), 623-629, 2005 | 109 | 2005 |
| Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines E Klechevsky, M Liu, R Morita, R Banchereau, L Thompson-Snipes, ... Human immunology 70 (5), 281-288, 2009 | 99 | 2009 |
| Molecular determinants of response to PD-L1 blockade across tumor types R Banchereau, N Leng, O Zill, E Sokol, G Liu, D Pavlick, S Maund, LF Liu, ... Nature communications 12 (1), 3969, 2021 | 96 | 2021 |
| Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated … RJ Motzer, T Powles, MB Atkins, B Escudier, DF McDermott, BY Alekseev, ... JAMA oncology 8 (2), 275-280, 2022 | 93 | 2022 |
Alma-Martina CepikaStanford MedicineVerified email at stanford.edu
